Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer

RECRUITING

NCT07226999

PHASE2/PHASE3

Sponsor: Pfizer

Summary

This study is being done to learn more about a new medicine called PF-08634404 and how well it works when given with chemotherapy to adults with extensive-stage small cell lung cancer (ES-SCLC), a fast-growing type of lung cancer that has spread widely in the body. To join the study, participants must meet the following conditions: * Be 18 years or older. * Have extensive-stage small cell lung cancer confirmed by lab tests. * Have not received chemotherapy or radiation for this type of lung cancer. * Be in good physical condition and have healthy organs based on medical tests. The study has two parts: * In the first part, researchers will check how safe the study medicine is and how well people tolerate it when given with chemotherapy. * In the second part, they will compare study medicine plus chemotherapy to another approved treatment (atezolizumab plus chemotherapy) to see which works better. Participants will receive the treatment through IV infusions (medicine given directly into a vein). The treatment will be given in repeated time periods called cycles. Some participants will continue receiving the study medicine alone after the initial treatment.

Official title: A GLOBAL PHASE 2/3 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

550

Start Date

2025-12-09

Completion Date

2034-03-11

Last Updated

2026-07-08

Healthy Volunteers

No

Conditions

Small Cell Lung Cancer (SCLC)

Interventions

DRUG

PF-08634404

Concentrate for solution for infusion

BIOLOGICAL

Atezolizumab

Injection for intravenous use

DRUG

Chemotherapy

Injection for intravenous use

Locations (49)

Highlands Oncology Group

Fayetteville, Arkansas, United States

BRCR Coral Springs

Coral Springs, Florida, United States

Mid Florida Hematology and Oncology Center

Orange City, Florida, United States

BRCR Global - Tamarac

Tamarac, Florida, United States

University Hospitals Cleveland Medical Center

Cleveland, Ohio, United States

Texas Oncology - Gulf Coast

Beaumont, Texas, United States

Texas Oncology - San Antonio

Fredericksburg, Texas, United States

Texas Oncology - Gulf Coast

Houston, Texas, United States

Texas Oncology - Gulf Coast

Houston, Texas, United States

US Oncology Investigational Product Center (IPC)

Irving, Texas, United States

Texas Oncology - San Antonio

New Braunfels, Texas, United States

Texas Oncology - Gulf Coast

Pearland, Texas, United States

Texas Oncology - San Antonio

San Antonio, Texas, United States

Texas Oncology - San Antonio

San Antonio, Texas, United States

Texas Oncology - San Antonio

San Antonio, Texas, United States

Texas Oncology - Gulf Coast

Sugar Land, Texas, United States

Texas Oncology -Sugar Land

Sugar Land, Texas, United States

Texas Oncology - Gulf Coast

The Woodlands, Texas, United States

Texas Oncology - Gulf Coast

Webster, Texas, United States